APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Abuse Treatment

Drug Abuse can be defined as habitually, dependence of an individual on any drugs, which turns into an addiction. Opioid, alcohol, tobacco and cigarettes are some of the common, drugs which has been misused leading to drugs addictions. In recent past, many products have been launched in market for treatment and management of drug abuse. Some commonly used drug for treatment of drugs abuse are Disulfiram, Acamprosate, Naltrexone, Nicotine Replacement Treatment, Methadone, and Buprenorphine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Drug Abuse can be defined as habitually, dependence of an individual on any drugs, which turns into an addiction. Opioid, alcohol, tobacco and cigarettes are some of the common, drugs which has been misused leading to drugs addictions. In recent past, many products have been launched in market for treatment and management of drug abuse. Some commonly used drug for treatment of drugs abuse are Disulfiram, Acamprosate, Naltrexone, Nicotine Replacement Treatment, Methadone, and Buprenorphine.

Selected research

Market Outlook & Growth Opportunities

Global Drug Abuse Treatment Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchDrug Abuse Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Abuse Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Drug Abuse Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Abuse Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Abuse Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Drug Abuse can be defined as habitually, dependence of an individual on any drugs, which turns into an addiction. Opioid, alcohol, tobacco and cigarettes are some of the common, drugs which has been misused leading to drugs addictions. In recent past, many products have been launched in market for treatment and management of drug abuse. Some commonly used drug for treatment of drugs abuse are Disulfiram, Acamprosate, Naltrexone, Nicotine Replacement Treatment, Methadone, and Buprenorphine.

North America is the largest Drug Abuse Treatment market with about 48% market share. Europe is follower, accounting for about 33% market share.The key manufacturers are Indivior, Pfizer, Alkermes, Novartis, Mylan, Cipla, Glenmark, Dr. Reddy's Laboratories, Teva Pharmaceutical, PLIVA (Odyssey) etc. Top 5 companies occupied about 14% market share.

This report provides an overview of the global Drug Abuse Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Drug Abuse Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Abuse Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Abuse Treatment market.

Drug Abuse Treatment Segment by Company

Indivior

Pfizer

Alkermes

Novartis

Mylan

Cipla

Glenmark

Dr. Reddy's Laboratories

Teva Pharmaceutical

PLIVA (Odyssey)

Drug Abuse Treatment Segment by Type

Opioid Addiction

Tobacco/Nicotine Addiction

Alcohol Dependence

Drug Abuse Treatment Segment by Application

Hospital & Clinics

Residential (non-hospital)

Drug Abuse Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Abuse Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Abuse Treatment key companies, revenue, market share, and recent developments.

3. To split the Drug Abuse Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Abuse Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Abuse Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Abuse Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Abuse Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Abuse Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Abuse Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Abuse Treatment industry.

Chapter 3: Detailed analysis of Drug Abuse Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Abuse Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Abuse Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Abuse Treatment Industry Trends Table 2. Drug Abuse Treatment Industry Drivers Table 3. Drug Abuse Treatment Industry Opportunities and Challenges Table 4. Drug Abuse Treatment Industry Restraints Table 5. Global Drug Abuse Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Abuse Treatment Revenue Share by Company (2021-2026) Table 7. Global Drug Abuse Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Abuse Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Drug Abuse Treatment Company, Product Type & Application Table 10. Global Drug Abuse Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Abuse Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Opioid Addiction Table 15. Significant Companies of Tobacco/Nicotine Addiction Table 16. Significant Companies of Alcohol Dependence Table 17. Global Drug Abuse Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drug Abuse Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drug Abuse Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drug Abuse Treatment Sales Value Share by Type (2021-2026) Table 21. Global Drug Abuse Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital & Clinics Table 23. Significant Companies of Residential (non-hospital) Table 24. Global Drug Abuse Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drug Abuse Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Drug Abuse Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Drug Abuse Treatment Sales Value Share by Application (2021-2026) Table 28. Global Drug Abuse Treatment Sales Value Share by Application (2027-2032) Table 29. Global Drug Abuse Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drug Abuse Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Drug Abuse Treatment Sales Value Share by Region (2021-2026) Table 32. Global Drug Abuse Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Drug Abuse Treatment Sales Value Share by Region (2027-2032) Table 34. Global Drug Abuse Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drug Abuse Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Drug Abuse Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Drug Abuse Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Drug Abuse Treatment Sales Value Market Share by Country (2027-2032) Table 39. Indivior Company Information Table 40. Indivior Business Overview Table 41. Indivior Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Indivior Drug Abuse Treatment Product Portfolio Table 43. Indivior Recent Development Table 44. Pfizer Company Information Table 45. Pfizer Business Overview Table 46. Pfizer Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Pfizer Drug Abuse Treatment Product Portfolio Table 48. Pfizer Recent Development Table 49. Alkermes Company Information Table 50. Alkermes Business Overview Table 51. Alkermes Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Alkermes Drug Abuse Treatment Product Portfolio Table 53. Alkermes Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis Drug Abuse Treatment Product Portfolio Table 58. Novartis Recent Development Table 59. Mylan Company Information Table 60. Mylan Business Overview Table 61. Mylan Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Mylan Drug Abuse Treatment Product Portfolio Table 63. Mylan Recent Development Table 64. Cipla Company Information Table 65. Cipla Business Overview Table 66. Cipla Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Cipla Drug Abuse Treatment Product Portfolio Table 68. Cipla Recent Development Table 69. Glenmark Company Information Table 70. Glenmark Business Overview Table 71. Glenmark Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Glenmark Drug Abuse Treatment Product Portfolio Table 73. Glenmark Recent Development Table 74. Dr. Reddy's Laboratories Company Information Table 75. Dr. Reddy's Laboratories Business Overview Table 76. Dr. Reddy's Laboratories Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Dr. Reddy's Laboratories Drug Abuse Treatment Product Portfolio Table 78. Dr. Reddy's Laboratories Recent Development Table 79. Teva Pharmaceutical Company Information Table 80. Teva Pharmaceutical Business Overview Table 81. Teva Pharmaceutical Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Teva Pharmaceutical Drug Abuse Treatment Product Portfolio Table 83. Teva Pharmaceutical Recent Development Table 84. PLIVA (Odyssey) Company Information Table 85. PLIVA (Odyssey) Business Overview Table 86. PLIVA (Odyssey) Drug Abuse Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. PLIVA (Odyssey) Drug Abuse Treatment Product Portfolio Table 88. PLIVA (Odyssey) Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Drug Abuse Treatment Product Image Figure 2. Global Drug Abuse Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Abuse Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Abuse Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Opioid Addiction Image Figure 8. Tobacco/Nicotine Addiction Image Figure 9. Alcohol Dependence Image Figure 10. Global Drug Abuse Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drug Abuse Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drug Abuse Treatment Sales Value Share by Type (2021-2032) Figure 13. Hospital & Clinics Image Figure 14. Residential (non-hospital) Image Figure 15. Global Drug Abuse Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drug Abuse Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drug Abuse Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Drug Abuse Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Drug Abuse Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Drug Abuse Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Drug Abuse Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Drug Abuse Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Drug Abuse Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Drug Abuse Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Drug Abuse Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Drug Abuse Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Drug Abuse Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Drug Abuse Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Drug Abuse Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Drug Abuse Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Opioid Addiction
  • Tobacco/Nicotine Addiction
  • Alcohol Dependence
Applications
  • Hospital & Clinics
  • Residential (non-hospital)
Companies covered
  • Indivior
  • Pfizer
  • Alkermes
  • Novartis
  • Mylan
  • Cipla
  • Glenmark
  • Dr. Reddy's Laboratories
  • Teva Pharmaceutical
  • PLIVA (Odyssey)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Abuse Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Abuse Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Abuse Treatment Market Dynamics
  1. 2.1 Drug Abuse Treatment Industry Trends
  2. 2.2 Drug Abuse Treatment Industry Drivers
  3. 2.3 Drug Abuse Treatment Industry Opportunities and Challenges
  4. 2.4 Drug Abuse Treatment Industry Restraints
3 Drug Abuse Treatment Market by Company
  1. 3.1 Global Drug Abuse Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Drug Abuse Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Drug Abuse Treatment Company Ranking (2024-2026)
  4. 3.4 Global Drug Abuse Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Abuse Treatment Company Product Type and Application
  6. 3.6 Global Drug Abuse Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Abuse Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Abuse Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Abuse Treatment Market by Type
  1. 4.1 Drug Abuse Treatment Type Introduction
  2. 4.1.1 Opioid Addiction
  3. 4.1.2 Tobacco/Nicotine Addiction
  4. 4.1.3 Alcohol Dependence
  5. 4.2 Global Drug Abuse Treatment Sales Value by Type
  6. 4.2.1 Global Drug Abuse Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drug Abuse Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drug Abuse Treatment Sales Value Share by Type (2021-2032)
5 Drug Abuse Treatment Market by Application
  1. 5.1 Drug Abuse Treatment Application Introduction
  2. 5.1.1 Hospital & Clinics
  3. 5.1.2 Residential (non-hospital)
  4. 5.2 Global Drug Abuse Treatment Sales Value by Application
  5. 5.2.1 Global Drug Abuse Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drug Abuse Treatment Sales Value by Application (2021-2032)
  7. 5.2.3 Global Drug Abuse Treatment Sales Value Share by Application (2021-2032)
6 Drug Abuse Treatment Regional Value Analysis
  1. 6.1 Global Drug Abuse Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Abuse Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Abuse Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Abuse Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Abuse Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Drug Abuse Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Abuse Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Abuse Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Abuse Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Abuse Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Abuse Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Drug Abuse Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Abuse Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Abuse Treatment Sales Value Share by Country, 2025 VS 2032
7 Drug Abuse Treatment Country-level Value Analysis
  1. 7.1 Global Drug Abuse Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Abuse Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Abuse Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Abuse Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Abuse Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Abuse Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Abuse Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Indivior
  2. 8.1.1 Indivior Company Information
  3. 8.1.2 Indivior Business Overview
  4. 8.1.3 Indivior Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Indivior Drug Abuse Treatment Product Portfolio
  6. 8.1.5 Indivior Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Drug Abuse Treatment Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Alkermes
  14. 8.3.1 Alkermes Company Information
  15. 8.3.2 Alkermes Business Overview
  16. 8.3.3 Alkermes Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Alkermes Drug Abuse Treatment Product Portfolio
  18. 8.3.5 Alkermes Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Drug Abuse Treatment Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Drug Abuse Treatment Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Cipla
  32. 8.6.1 Cipla Company Information
  33. 8.6.2 Cipla Business Overview
  34. 8.6.3 Cipla Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cipla Drug Abuse Treatment Product Portfolio
  36. 8.6.5 Cipla Recent Developments
  37. 8.7 Glenmark
  38. 8.7.1 Glenmark Company Information
  39. 8.7.2 Glenmark Business Overview
  40. 8.7.3 Glenmark Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Glenmark Drug Abuse Treatment Product Portfolio
  42. 8.7.5 Glenmark Recent Developments
  43. 8.8 Dr. Reddy's Laboratories
  44. 8.8.1 Dr. Reddy's Laboratories Company Information
  45. 8.8.2 Dr. Reddy's Laboratories Business Overview
  46. 8.8.3 Dr. Reddy's Laboratories Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dr. Reddy's Laboratories Drug Abuse Treatment Product Portfolio
  48. 8.8.5 Dr. Reddy's Laboratories Recent Developments
  49. 8.9 Teva Pharmaceutical
  50. 8.9.1 Teva Pharmaceutical Company Information
  51. 8.9.2 Teva Pharmaceutical Business Overview
  52. 8.9.3 Teva Pharmaceutical Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Pharmaceutical Drug Abuse Treatment Product Portfolio
  54. 8.9.5 Teva Pharmaceutical Recent Developments
  55. 8.10 PLIVA (Odyssey)
  56. 8.10.1 PLIVA (Odyssey) Company Information
  57. 8.10.2 PLIVA (Odyssey) Business Overview
  58. 8.10.3 PLIVA (Odyssey) Drug Abuse Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PLIVA (Odyssey) Drug Abuse Treatment Product Portfolio
  60. 8.10.5 PLIVA (Odyssey) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst